IL188322A0 - Nanoparticulate megestrol formulations - Google Patents

Nanoparticulate megestrol formulations

Info

Publication number
IL188322A0
IL188322A0 IL188322A IL18832207A IL188322A0 IL 188322 A0 IL188322 A0 IL 188322A0 IL 188322 A IL188322 A IL 188322A IL 18832207 A IL18832207 A IL 18832207A IL 188322 A0 IL188322 A0 IL 188322A0
Authority
IL
Israel
Prior art keywords
nanoparticulate megestrol
megestrol formulations
formulations
nanoparticulate
megestrol
Prior art date
Application number
IL188322A
Other languages
English (en)
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of IL188322A0 publication Critical patent/IL188322A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL188322A 2005-06-22 2007-12-20 Nanoparticulate megestrol formulations IL188322A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69312705P 2005-06-22 2005-06-22
PCT/US2006/024349 WO2007002315A2 (en) 2005-06-22 2006-06-22 Nanoparticulate megestrol formulations

Publications (1)

Publication Number Publication Date
IL188322A0 true IL188322A0 (en) 2008-04-13

Family

ID=37595838

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188322A IL188322A0 (en) 2005-06-22 2007-12-20 Nanoparticulate megestrol formulations

Country Status (13)

Country Link
EP (1) EP1901713A2 (ja)
JP (1) JP2008546796A (ja)
KR (1) KR20080024213A (ja)
CN (1) CN101242810A (ja)
AU (1) AU2006262144A1 (ja)
BR (1) BRPI0612665A2 (ja)
CA (1) CA2613466A1 (ja)
EA (1) EA200800099A1 (ja)
IL (1) IL188322A0 (ja)
MX (1) MX2008000396A (ja)
NO (1) NO20080403L (ja)
WO (1) WO2007002315A2 (ja)
ZA (1) ZA200800376B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105147605B (zh) * 2015-06-24 2019-04-19 中国人民解放军军事医学科学院毒物药物研究所 黄体酮纳米组合物及其制备方法
CN105687027A (zh) * 2016-01-26 2016-06-22 中国科学院生物物理研究所 一种无醇氨基酸型免冲洗泡沫洗液
CN105769763A (zh) * 2016-05-25 2016-07-20 西安德天药业股份有限公司 一种醋酸甲地孕酮纳米混悬液及其制备方法和应用
CN108409821A (zh) * 2018-03-19 2018-08-17 青岛国海生物制药有限公司 一种醋酸甲地孕酮纳米结晶的制备方法及醋酸甲地孕酮
CN108309933A (zh) * 2018-03-19 2018-07-24 青岛国海生物制药有限公司 一种口服醋酸甲地孕酮纳米混悬液及其制备方法
CN112891309B (zh) * 2019-11-19 2022-07-26 北京化工大学 一种醋酸甲地孕酮纳米干混悬剂及其制备方法
CN111643463A (zh) * 2020-07-08 2020-09-11 西安远大德天药业股份有限公司 一种醋酸甲地孕酮分散片及其制备方法
CN111930838B (zh) * 2020-07-23 2023-05-16 金陵科技学院 一种面向时间的分布式档案管理方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO2003086354A1 (en) * 2002-04-12 2003-10-23 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
JP4787165B2 (ja) * 2003-11-05 2011-10-05 エラン ファーマ インターナショナル,リミティド 表面安定剤としてペプチドを有するナノ粒子組成物

Also Published As

Publication number Publication date
KR20080024213A (ko) 2008-03-17
NO20080403L (no) 2008-03-19
WO2007002315A3 (en) 2007-04-05
CN101242810A (zh) 2008-08-13
ZA200800376B (en) 2009-03-25
EP1901713A2 (en) 2008-03-26
JP2008546796A (ja) 2008-12-25
BRPI0612665A2 (pt) 2010-11-30
WO2007002315A2 (en) 2007-01-04
AU2006262144A1 (en) 2007-01-04
EA200800099A1 (ru) 2008-06-30
MX2008000396A (es) 2009-02-23
CA2613466A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
GB2424581B (en) Formulations
IL187258A0 (en) Nanoparticulate clopidogrel formulations
ZA200705384B (en) Nanoparticulate candesartan formulations
ZA200710764B (en) Nanoparticulate acetaminophen formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
IL188733A0 (en) Immunoconjugate formulations
IL186609A0 (en) Nanoparticulate quinazoline derivative formulations
ZA200707654B (en) Formulations
EP1861104A4 (en) IMPROVED GACYCLIDINE FORMULATIONS
EP1951693A4 (en) SOLID FORMULATIONS
GB0503359D0 (en) Insecticidal composition
ZA200800376B (en) Nanoparticulate megestrol formulations
GB2424585B (en) Speculum
IL192149A0 (en) Stable s-nitrosothiol formulations
ZA200800365B (en) Substituted tetrahydroqulnolines
IL187128A0 (en) Stable nanoparticle formulations
ZA200800146B (en) Immunoconjugate formulations
GB2443771B (en) Speculum
GB0522917D0 (en) Formulations
GB0520388D0 (en) Formulations
GB0526322D0 (en) Formulations
GB0518878D0 (en) Formulations
GB0500913D0 (en) Novel formulations
GB0500912D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations